EORTC presents European solution for effective cancer drug development
Drug developers are facing the perfect storm. They are confronted with major patent expiries, increased payer scrutiny, changing priorities, shifting business models, increased risk averseness, increased clinical trial costs, ...
Jul 1, 2014
0
0